Clinical trials: Controlled Hypertension
Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label…
- Trial name
- NCT02279160
- Testing
- APD811
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 61 people
- Sponsor
- United Therapeutics
Mild Hypertension
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
This was a Phase 2, double-blind, randomized, placebo-controlled study of IONIS-AGT-LRx conducted in mild hypertensive participants.
- Trial name
- NCT03714776
- Testing
- ISIS 757456
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
This is a Phase 4, prospective, multi-centric and randomized controlled study to compare the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous system's (SNS) activity in subjects with…
- Trial name
- NCT01251146
- Testing
- Bisoprolol, Atenolol
- Where
- 2 sites in China
- Volunteers
- 177 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Hyperkalemia, Resistant Hypertension
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone…
- Trial name
- AMBER (NCT03071263)
- Testing
- Patiromer, Spironolactone
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 295 people
- Sponsor
- Relypsa, Inc.
Hypertension
The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension
In this research study, the investigators are interested in learning how extracts from grape seeds can help those individuals with high blood pressure.
- Trial name
- GSE (NCT00979732)
- Testing
- grape seed extract
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Pulmonary Arterial Hypertension
Beraprost-314d Added-on to Tyvaso® (BEAT)
This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in patients with pulmonary arterial hypertension.
- Trial name
- BEAT (NCT01908699)
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Where
- 75 sites in United States, Israel
- Volunteers
- 273 people
- Sponsor
- Lung Biotechnology PBC
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Hypertension
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed treatment options exist.
- Trial name
- AMBER I (NCT01884675)
- Testing
- Ambrisentan 5 mg
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular disease.
- Conditions
- Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
- Trial name
- ESRA (NCT05339087)
- Testing
- Riociguat Oral Tablet
- Where
- 8 sites in Austria, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Heidelberg University
Uncontrolled Hypertension, Chronic Kidney Diseases
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
- Trial name
- NCT05432167
- Testing
- CIN-107
- Where
- 71 sites in United States
- Volunteers
- 195 people
- Sponsor
- AstraZeneca
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Hypertension
Controlling and Lowering Blood Pressure With The MOBIUSHD™
To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.
- Trial name
- CALM-FIM_US (NCT01831895)
- Testing
- MobiusHD™
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Vascular Dynamics, Inc.
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension Treatment Trial
Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder of elevated intracranial pressure of unknown cause [Corbett, et al., 1982; Wall, et al., 1991].
- Trial name
- IIHTT (NCT01003639)
- Testing
- Acetazolamide, Formal weight loss counselling program
- Where
- 41 sites in United States, Canada
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Glaucoma, Optic Neuropathy
Use of Bevacizumab in Trabeculectomy Surgery
When a patient with glaucoma who has a pressure that is too high and causing damage to their vision, despite receiving the maximum amount of medication that can be tolerated, the decision is made to have glaucoma surgery.
- Conditions
- Glaucoma, Optic Neuropathy, Fibrosis
- Trial name
- NCT01166594
- Testing
- Bevacizumab, Control
- Where
- Canada
- Volunteers
- 59 people
- Sponsor
- Sunnybrook Health Sciences Centre
Pulmonary Arterial Hypertension
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH.
- Trial name
- SERAPHIN (NCT00660179)
- Testing
- macitentan (ACT-064992)
- Where
- 153 sites in United States, Argentina and 36 more
- Volunteers
- 742 people
- Sponsor
- Actelion
Hypertension
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
- Trial name
- NCT00281580
- Testing
- Amlodipine 5 mg, Telmisartan 20 mg, Telmisartan 40 mg
- Where
- 136 sites in United States, Argentina and 3 more
- Volunteers
- 1,461 people
- Sponsor
- Boehringer Ingelheim
Safety Issues, Tolerance
First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects
This is a FIH, double-blind, placebo-controlled, within-group randomised, trial designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending oral doses of compound 106 (C106) in…
- Conditions
- Safety Issues, Tolerance, Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Trial name
- NCT05427253
- Testing
- C106 solution
- Where
- Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vicore Pharma AB
Open-Angle Glaucoma, Ocular Hypertension
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs…
- Trial name
- NCT02742649
- Testing
- Fixed Combination, Bimatoprost, Timolol
- Where
- Panama
- Volunteers
- 55 people
- Sponsor
- ForSight Vision5, Inc.